1. Current Landscape of iPSC Haplobanks.
- Author
-
Escribá R, Beksac M, Bennaceur-Griscelli A, Glover JC, Koskela S, Latsoudis H, Querol S, and Alvarez-Palomo B
- Subjects
- Humans, HLA Antigens genetics, HLA Antigens immunology, Regenerative Medicine, Cell- and Tissue-Based Therapy methods, Induced Pluripotent Stem Cells cytology, Induced Pluripotent Stem Cells metabolism, Haplotypes genetics
- Abstract
The use of allogeneic induced pluripotent stem cell (iPSC)-derived cell therapies for regenerative medicine offers an affordable and realistic alternative to producing individual iPSC lines for each patient in need. Human Leukocyte Antigens (HLA)-homozygous iPSCs matched in hemi-similarity could provide cell therapies with reduced immune rejection covering a wide range of the population with a few iPSC lines. Several banks of HLA-homozygous iPSCs (haplobanks) have been established worldwide or are underway, to provide clinical grade starting material for cell therapies covering the most frequent HLA haplotypes for certain populations. Harmonizing quality standards among haplobanks and creating a global registry could minimize the collective effort and provide a much wider access to HLA-compatible cell therapies for patients with less frequent haplotypes. In this review we present all the current haplobank initiatives and their potential benefits for the global population., Competing Interests: Declarations Ethical Approval and Consent to Participate Not applicable. Consent for Publication Not applicable. Competing Interests The authors declare that they have no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF